Janssen Pharmaceuticals Inc., of Titusville, N.J., part of Johnson & Johnson, said a study in the April 2015 issue of The Journal of Clinical Psychiatry showed long-acting Invega Sustenna (paliperidone palmitate) was effective six months longer than other oral antipsychotics commonly prescribed for schizophrenia, and delayed relapses, which can result in hospitalization, arrest and incarceration.